Ardelyx Inc. Stock
Ardelyx Inc. Stock
Ardelyx, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines aimed at treating kidney and cardiovascular diseases. The company uses a unique approach to drug discovery, developing therapeutics that target ion channels and transporters, which play a critical role in regulating activities in the body. Ardelyx's lead product candidate, tenapanor, is being studied for the treatment of conditions such as hyperphosphatemia in patients with chronic kidney disease, irritable bowel syndrome with constipation, and diverticulosis. The company is listed on the NASDAQ exchange under the ticker symbol ARDX.
Pros and Cons of Ardelyx Inc. in the next few years
Pros
Cons
Performance of Ardelyx Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ardelyx Inc. | 0.910% | -2.116% | -15.296% | 40.514% | 4.048% | -12.204% | - |
| Brainstorm Cell | 1.170% | -1.874% | -1.485% | -81.975% | 114.440% | -80.717% | - |
| Salarius Pharmaceuticals Inc. | -3.170% | 2.315% | -15.000% | -67.971% | -20.360% | -98.187% | -99.994% |
| Krystal Biotech | 0.170% | -7.154% | -4.744% | 92.987% | 28.103% | - | - |
News
3 mid-caps under $20 that Wall Street loves
Just three trading weeks into the new year, a half dozen U.S. mid- or large-cap stocks are already up 20% or more.
Picking up where it left off last year, artificial intelligence (AI) data center
Why Ardelyx Stock Soared Today
Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results.
Ardelyx's quarterly revenue skyrocketed to $56.4
